Li D, Hu X, Tian Z, Ning Q, Liu J, Yue Y
Acta Pharmacol Sin. 2025; .
PMID: 39856433
DOI: 10.1038/s41401-024-01467-6.
Shoemaker R, Huang M, Wu Y, Huang C, Lee D
NAR Cancer. 2024; 6(3):zcae037.
PMID: 39329012
PMC: 11426327.
DOI: 10.1093/narcan/zcae037.
Pan M, Solozobova V, Kuznik N, Jung N, Grassle S, Gourain V
Cancer Res Commun. 2023; 3(7):1378-1396.
PMID: 37520743
PMC: 10373600.
DOI: 10.1158/2767-9764.CRC-23-0111.
Meidinna H, Shefrin S, Sari A, Zhang H, Dhanjal J, Kaul S
Front Cell Dev Biol. 2022; 10:918970.
PMID: 36172283
PMC: 9510692.
DOI: 10.3389/fcell.2022.918970.
Shefrin S, Sari A, Kumar V, Zhang H, Meidinna H, Kaul S
Curr Res Struct Biol. 2022; 4:320-331.
PMID: 36164647
PMC: 9507986.
DOI: 10.1016/j.crstbi.2022.09.002.
The mitochondrial unfolded protein response (UPR): shielding against toxicity to mitochondria in cancer.
Inigo J, Chandra D
J Hematol Oncol. 2022; 15(1):98.
PMID: 35864539
PMC: 9306209.
DOI: 10.1186/s13045-022-01317-0.
Why is Mortalin a Potential Therapeutic Target for Cancer?.
Yoon A, Wadhwa R, Kaul S, Yun C
Front Cell Dev Biol. 2022; 10:914540.
PMID: 35859897
PMC: 9290191.
DOI: 10.3389/fcell.2022.914540.
The Role of Heat Shock Protein 70 Subfamily in the Hyperplastic Prostate: From Molecular Mechanisms to Therapeutic Opportunities.
Fu X, Liu H, Liu J, DiSanto M, Zhang X
Cells. 2022; 11(13).
PMID: 35805135
PMC: 9266107.
DOI: 10.3390/cells11132052.
Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far.
Elwakeel A
Front Cell Dev Biol. 2022; 10:879632.
PMID: 35493098
PMC: 9047732.
DOI: 10.3389/fcell.2022.879632.
Pre-clinical safety and therapeutic efficacy of a plant-based alkaloid in a human colon cancer xenograft model.
Freeling J, Scholl J, Eikanger M, Knoblich C, Potts R, Anderson D
Cell Death Discov. 2022; 8(1):135.
PMID: 35347121
PMC: 8960818.
DOI: 10.1038/s41420-022-00936-3.
Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53 mutant: bioinformatics and experimental evidence.
Radhakrishnan N, Dhanjal J, Sari A, Ishida Y, Terao K, Kaul S
Discov Oncol. 2022; 12(1):64.
PMID: 35201513
PMC: 8777538.
DOI: 10.1007/s12672-021-00461-2.
GRP75 mediates endoplasmic reticulum-mitochondria coupling during palmitate-induced pancreatic β-cell apoptosis.
Tiwary S, Nandwani A, Khan R, Datta M
J Biol Chem. 2021; 297(6):101368.
PMID: 34756890
PMC: 8637649.
DOI: 10.1016/j.jbc.2021.101368.
Mitochondrial HSP70 Chaperone System-The Influence of Post-Translational Modifications and Involvement in Human Diseases.
Havalova H, Ondrovicova G, Keresztesova B, Bauer J, Pevala V, Kutejova E
Int J Mol Sci. 2021; 22(15).
PMID: 34360841
PMC: 8347752.
DOI: 10.3390/ijms22158077.
PSPC1 is a new contextual determinant of aberrant subcellular translocation of oncogenes in tumor progression.
Lang Y, Jou Y
J Biomed Sci. 2021; 28(1):57.
PMID: 34340703
PMC: 8327449.
DOI: 10.1186/s12929-021-00753-3.
Mutant p53 Harboring Luminal-A Breast Cancer Cells Are Refractory to Apoptosis and Cell Cycle Arrest in Response to Mortaparib, a Multimodal Small Molecule Inhibitor.
Elwakeel A, Sari A, Dhanjal J, Meidinna H, Sundar D, Kaul S
Cancers (Basel). 2021; 13(12).
PMID: 34207240
PMC: 8234533.
DOI: 10.3390/cancers13123043.
Characterization of Exosomes in Plasma of Patients with Breast, Ovarian, Prostate, Hepatic, Gastric, Colon, and Pancreatic Cancers.
Huang M, Xia M, Gao Z, Zhou H, Liu M, Huang S
J Cancer Ther. 2021; 10(5):382-399.
PMID: 33833900
PMC: 8025783.
DOI: 10.4236/jct.2019.105032.
Identification and Characterization of Mortaparib-A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms.
Sari A, Elwakeel A, Dhanjal J, Kumar V, Sundar D, Kaul S
Cancers (Basel). 2021; 13(4).
PMID: 33671256
PMC: 7921971.
DOI: 10.3390/cancers13040835.
Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability.
Wu P, Hong S, Starenki D, Oshima K, Shao H, Gestwicki J
Oncogene. 2020; 39(21):4257-4270.
PMID: 32291414
PMC: 7244387.
DOI: 10.1038/s41388-020-1285-5.
β-Actin facilitates etoposide-induced p53 nuclear import.
Qi W, Li J, Pei X, Ke Y, Bu Q, Ni X
J Biosci. 2020; 45.
PMID: 32098913
Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri J, Bhargava P, Dhanjal J, Yaguchi T, Sundar D, Kaul S
J Exp Clin Cancer Res. 2019; 38(1):499.
PMID: 31856867
PMC: 6923857.
DOI: 10.1186/s13046-019-1500-9.